This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q75.4 | Special Copayment Reduction: V182 | Re-certification cycle: 5 years |
| B. Synonyms | Franceschetti syndrome, Treacher Collins syndrome |
| C. Adult onset | Likelihood of first onset in adulthood very low — mandibulofacial dysostosis is a congenital abnormality of facial skeletal development whose findings are evident at birth. Cases of a mild phenotype first diagnosed in adulthood are rare, but some patients live undiagnosed with only facial findings and without raised intracranial pressure, and are first diagnosed in adulthood when seeking hearing rehabilitation or corrective surgery. |
| 1. History | 1847, first description by Thomson. 1900, description of typical cases by Treacher Collins. 1949, named 'mandibulofacial dysostosis' by Franceschetti and Klein. 1996, identification of the TCOF1 gene. 2012, additional discovery of POLR1C and POLR1D. |
| 2. Causes | Abnormal migration and proliferation of neural crest cells (NCC) derived from the 1st and 2nd pharyngeal arches. Variants in TCOF1 (treacle protein), POLR1C, POLR1D. Suppression of rDNA transcription → increased p53-mediated NCC apoptosis. |
| 3. Genetics | TCOF1 (AD, 5q32-q33.1, about 78%), POLR1C (AR, 6p21.1), POLR1D (AD/AR, 13q12.2). Incomplete penetrance and phenotypic variability. About 60% of TCOF1 cases are de novo mutations. |
| 4. General epidemiology | About 1 in 50,000 births. No sex difference. No ethnic predilection identified. A rare cause among all craniofacial malformations. Korea: rare disease registered for Special Copayment Reduction (V182). |
| 5. Pathophysiology | Loss of treacle protein function → reduced activity of rDNA transcription factors (UBF, Pol I) → reduced production of precursor ribosomal RNA → p53-dependent apoptosis of neural crest cells → failure of formation of facial skeleton derived from the 1st and 2nd pharyngeal arches. |
| 6. Symptoms | Downslanting palpebral fissures (antimongoloid slant), zygomatic and mandibular hypoplasia, microtia and external auditory canal atresia (conductive hearing loss), lower orbital defect, cleft palate and choanal stenosis, airway narrowing (sleep apnea). |
| 7. Signs | Bilaterally symmetric zygomatic and mandibular hypoplasia, microtia and external auditory canal atresia, lower eyelid coloboma, downslanting palpebral fissures, malar hypoplasia. Hearing test: conductive hearing loss. CT: zygomatic and mandibular bone hypoplasia, ossicular abnormalities. |
| 8. Screening | Prenatal ultrasound (facial and auricular abnormalities, micrognathia). Neonatal evaluation of facial morphology, hearing, and airway. Prenatal genetic testing in families with a family history. |
| 9. Diagnosis | Clinical diagnosis (characteristic facial findings) + TCOF1·POLR1C·POLR1D genetic testing. Temporal bone CT (ossicular abnormalities), 3D facial CT. Hearing tests. Polysomnography. |
| 10. Treatment | Securing the airway in the neonatal period (including tracheostomy). Bone conduction hearing aid (BAHA). Staged facial reconstruction (zygomatic and mandibular reconstruction, external ear reconstruction, eyelid correction). Distraction osteogenesis. Speech and hearing rehabilitation. |
| 11. Prognosis | Normal intelligence (no raised intracranial pressure). Normal language development possible after hearing rehabilitation. Repeated facial surgeries needed. Psychosocial support important. Occupational and social participation achievable in adulthood. |
| 12. Prevention | Genetic counseling and prenatal diagnosis. Early hearing rehabilitation (prevention of impaired language development). Early airway management. Psychological support. |
| 13. References | Treacher Collins Syndrome Collaborative Group. Positional cloning of a gene involved in the pathogenesis of Treacher Collins syndrome. Nat Genet. 1996 and 9 other references |
The first clinical description of mandibulofacial dysostosis dates to 1847, when the British ophthalmologist Allen Thomson reported a patient with downslanting palpebral fissures and facial malformation. Later, George Andreas in 1889 and the British ophthalmologist Edward Treacher Collins in 1900 described in detail two cases with lower orbital defects, eyelid coloboma, zygomatic hypoplasia, and ear abnormalities. The name 'Treacher Collins syndrome' derives from this second description.
In 1949, the Swiss ophthalmologists Adolphe Franceschetti and David Klein described the broad phenotypic spectrum and familial inheritance pattern of this disease, proposed the name 'mandibulofacial dysostosis', and established a classification system. In honor of their work, it is also called 'Franceschetti-Klein syndrome'. During this period the autosomal dominant inheritance pattern was recognized, and phenotypic variability and incomplete penetrance were shown to be characteristic.
The molecular genetic cause was identified in 1996 when the Treacher Collins Syndrome Collaborative Group identified the TCOF1 gene on chromosome 5q32-q33 and published in Nature Genetics that mutations in this gene cause Treacher Collins syndrome. The protein encoded by TCOF1 was named treacle and was shown to be involved in ribosomal RNA (rRNA) transcription in the nucleolus.
Between 2008 and 2012, two new causative genes were discovered in addition to TCOF1. POLR1D (2012, autosomal dominant or recessive) and POLR1C (2012, autosomal recessive) were shown to encode subunits of RNA polymerase I and to cause mandibulofacial dysostosis. This established mandibulofacial dysostosis as a 'ribosomopathy' caused by abnormalities of the ribosome biogenesis pathway. Results from experiments in animal models (zebrafish, mouse) showing that administration of a p53 inhibitor (pifithrin-α) and NAC (N-acetylcysteine) alleviates the phenotype suggest possible clinical application. Currently, genetic diagnosis-based management of mandibulofacial dysostosis is also provided at major medical institutions in Korea.
The pathogenesis of mandibulofacial dysostosis is abnormal development of neural crest cells (NCC), which are key to facial skeletal formation. Neural crest cells originate on the dorsal side of the embryonic neural tube and migrate ventrally to form the mesenchyme of the 1st and 2nd pharyngeal arches, from which most of the facial skeleton differentiates, including the zygomatic bone, mandible, ossicles, external ear, and temporal bone. In mandibulofacial dysostosis, abnormalities in the migration, proliferation, and survival of these neural crest cells cause hypoplasia of structures derived from the 1st and 2nd pharyngeal arches.
The TCOF1 gene and treacle protein: the TCOF1 gene, the most common cause, encodes treacle, a nucleolar protein. Treacle binds upstream binding factor (UBF) at the nucleolar organizer region (NOR), regulates RNA polymerase I (Pol I) activity, and is a key factor promoting transcription of ribosomal DNA (rDNA). When treacle function is lost, rDNA transcription is suppressed and production of precursor ribosomal RNA (pre-rRNA) decreases, and the resulting nucleolar stress activates the p53 pathway, increasing apoptosis of neural crest cells.
POLR1C and POLR1D genes: POLR1C and POLR1D encode subunits of RNA polymerases I and III, respectively, and their variants also cause the same neural crest cell abnormalities through impaired rDNA transcription. POLR1C variants follow autosomal recessive inheritance, and POLR1D variants can be inherited as autosomal dominant or recessive. Because all three genes are involved in the ribosome biogenesis pathway, mandibulofacial dysostosis is classified as a 'ribosomopathy'. Common mechanisms with other ribosomopathies such as Diamond-Blackfan anemia and Shwachman-Diamond syndrome are attracting attention.
Animal model studies: mandibulofacial dysostosis-like facial malformations were reproduced in zebrafish and mouse Tcof1 heterozygous deficiency models. In these models, a p53 inhibitor (pifithrin-α) or concurrent p53 gene deficiency was shown to reduce neural crest cell death and partially rescue the phenotype. In addition, NAC (N-acetylcysteine) administration reduced oxidative stress and showed a phenotype-alleviating effect. These studies provide a basis for translational clinical research on the possibility of alleviating the phenotype of mandibulofacial dysostosis during pregnancy (chemoprevention).
Three main genes are known as genetic causes of mandibulofacial dysostosis, each following a different mode of inheritance.
TCOF1 gene (5q32-q33.1): TCOF1 variants are identified in about 78–81% of all mandibulofacial dysostosis and follow autosomal dominant (AD) inheritance. Variants are distributed throughout the gene, and frameshift mutations due to insertions or deletions are the most common (about 60%). Splice site variants, nonsense variants, and missense variants are reported in that order. More than 200 pathogenic variants are currently registered in databases. Incomplete penetrance and variable expressivity are characteristic, so severity differs greatly even among family members with the same variant. About 60% of all patients are sporadic cases due to de novo mutations.
POLR1D gene (13q12.2): POLR1D variants are identified in about 9–11% of all cases and can be inherited as autosomal dominant or recessive. The POLR1D protein is a shared subunit (RPC2/AC40) of RNA Pol I and III and is involved in assembly of several RNA polymerase complexes. POLR1D variants tend to show a milder phenotype than TCOF1 variants. POLR1C gene (6p21.1): POLR1C variants are identified in about 5–6% of all cases and follow autosomal recessive (AR) inheritance. The POLR1C protein is a subunit (RPA2/AC40) of RNA Pol I and III and forms a heterodimer with POLR1D. Given AR inheritance, the parents are carriers and there is a 25% recurrence risk. Rarely, genetic testing is negative for all three genes, in which case discovery of additional causative genes is anticipated.
Genotype-phenotype correlation: in general, the phenotypic spectrum is broadest in patients with TCOF1 variants, and patients with POLR1C variants are reported to tend toward the most severe phenotype (severe micrognathia, airway narrowing), but this correlation varies greatly between individuals. Some associations between variant location (such as the C-terminal HEAT repeat domain) and phenotype severity have also been reported, but their predictive value is limited. Because diagnosis is difficult when the clinical phenotype is mild, genetic analysis is important for finding undiagnosed carriers when there is a family history of facial malformation.
Mandibulofacial dysostosis is a rare congenital facial malformation reported to occur at a frequency of about 1 in 50,000 births worldwide. Some studies report 1 in 25,000–50,000, and including undiagnosed mild phenotypes, the actual frequency is presumed to be higher.
Sex differences: because inheritance is autosomal dominant and recessive, there is no sex predilection, and males and females are affected with equal frequency. Regional and ethnic distribution: no differences in incidence among specific ethnic groups or regions have been reported. The form related to POLR1C variants, which follows autosomal recessive inheritance, may have a higher incidence in populations with high rates of consanguineous marriage. Because the proportion of de novo mutations is high, it occurs even without a family history.
De novo mutations versus inherited cases: about 60% of all mandibulofacial dysostosis are sporadic cases due to de novo mutations, and the remaining 40% are inherited from an affected parent. In familial cases, the phenotype of the affected parent is often mild, so the family history is sometimes mistakenly considered negative. Clinical evaluation of both parents of the patient is therefore important in genetic counseling.
Epidemiology in Korea: in Korea, mandibulofacial dysostosis is managed as a rare disease designated for National Health Insurance Special Copayment Reduction (V182). The number of newly diagnosed patients per year is in the tens, which qualifies it as ultra-rare, and the diagnosis rate is increasing with improved access to molecular genetic diagnosis. Diagnosis and treatment are provided through craniofacial multidisciplinary clinics at major Korean medical institutions (Seoul National University, Asan, Samsung, Severance, etc.). In some cases, evaluation for causative facial malformations, including mandibulofacial dysostosis, begins when conductive hearing loss is found on newborn hearing screening.
The pathogenesis of mandibulofacial dysostosis is understood as a neural crest cell (NCC) abnormality caused by a defect in the ribosome biogenesis pathway. In normal development, neural crest cells originate at the dorsal border of the embryonic neural tube, migrate actively ventrally, and form the mesenchymal cells of the 1st and 2nd pharyngeal arches. From this mesenchyme the facial skeleton (zygomatic bone, mandible, temporal bone, ossicles), external ear, and some eyelid structures differentiate.
Normal function of treacle and consequences of TCOF1 deficiency: the treacle protein localizes to rDNA transcription sites in the nucleolus and promotes production of 18S and 28S rRNA through assembly of the Pol I complex and activation of UBF (Upstream Binding Factor). Treacle is also involved in rDNA chromatin remodeling and DNA damage repair. In TCOF1 haploinsufficiency, ribosomal rRNA production decreases, triggering a nucleolar stress response. Nucleolar stress triggers stabilization and transcriptional activation of p53 protein through sequestration of MDM2 (an E3 ubiquitin ligase) at rDNA sites. Activated p53 induces p21 upregulation (cell cycle arrest) and mitochondrial-pathway apoptosis via Bax/Puma in neural crest cells.
Selective vulnerability of neural crest cells: during embryonic development, neural crest cells have a high demand for ribosome synthesis to support active proliferation and migration, making them particularly vulnerable to reduced ribosome biogenesis. In contrast, already differentiated cells have relatively low ribosome demand and are less affected. This selective vulnerability explains why, in mandibulofacial dysostosis, only facial structures derived from the 1st and 2nd pharyngeal arches are selectively affected without serious abnormalities in other organ systems. This mechanism has been directly confirmed in the mouse Tcof1 heterozygous model and the zebrafish tcof1 model.
Mechanism of phenotypic variability: modifier genes, epigenetic differences, and the maternal environment (folate status, exposure to oxidative stress) have been proposed as reasons why phenotypic severity differs greatly even with the same TCOF1 variant. There are studies showing that folate supplementation partially restores rDNA transcription in some animal models, suggesting that folate supplementation during pregnancy may contribute to alleviating the phenotype, but clinical evidence has not yet been established.
The clinical symptoms of mandibulofacial dysostosis reflect symmetric hypoplasia of structures derived from the 1st and 2nd pharyngeal arches, and abnormalities of the facial skeleton, hearing, airway, and eyelids predominate without raised intracranial pressure.
Characteristic facial findings: the most prominent feature is downslanting palpebral fissures (antimongoloid slant), with the lateral canthus positioned lower than the medial canthus. This is due to the low position of the lateral orbital rim caused by zygomatic hypoplasia. Lower eyelid coloboma appears as an eyelid defect with absent eyelashes in the medial 1/3 of the lower eyelid and is observed in about 70–80%. Hypoplasia of the zygomatic arch and malar region causes flattening and depression of the mid-to-lower face, producing the distinctive 'bird-face' or 'fish-face' appearance.
Mandibular and oral symptoms: micrognathia and retrognathia are characteristic and in severe cases cause upper airway narrowing and airway obstruction. Cleft palate is present in about 30–35%. Dental abnormalities (malocclusion, missing teeth, abnormal tooth shape) are also common. Limited mouth opening (trismus) causes difficulty with eating and endotracheal intubation. Hearing abnormalities: microtia (hypoplasia of the auricle) appears in about 80–90%, and atresia or stenosis of the external auditory canal is common. The resulting conductive hearing loss occurs in most patients and, if neglected, is an important cause of delayed language development. Ossicular (malleus, incus, stapes) malformations are often present. Airway symptoms: pharyngeal narrowing due to micrognathia and midface hypoplasia causes obstructive sleep apnea (OSA), and in more severe patients serious airway narrowing may occur from the neonatal period. Choanal stenosis is also rarely present.
The physical signs of mandibulofacial dysostosis are characteristic from immediately after birth and are confirmed by facial morphology assessment, hearing tests, airway evaluation, and imaging.
Facial morphological signs: on physical examination, bilaterally symmetric zygomatic and malar hypoplasia is prominent. The distance between the eyes (interpupillary distance) is normal, but the lateral canthi are displaced downward (antimongoloid slant). Absent eyelashes and eyelid defects (coloboma) are observed in the medial 1/3 of the lower eyelids. Microtia appears as a small, deformed, or absent auricle, and preauricular remnants (auricular tag/pit) may be present. Micrognathia appears as a receding mandible that makes the lower face look empty, and intraoral occlusal examination reveals an open bite or Class II malocclusion.
Hearing test findings: pure-tone audiometry (PTA) shows a bilateral conductive hearing loss pattern. Average hearing loss is about 50–60 dBHL (moderate to moderately severe), and severe hearing loss has also been reported in some. On otoacoustic emission (OAE) testing, emissions are reduced or absent when there is external auditory canal atresia or ossicular abnormality. Auditory brainstem response (ABR) is used to differentiate the presence of conductive loss and to quantify hearing thresholds. Imaging signs: facial CT shows hypoplasia or absence of the zygomatic arch, hypoplasia of the mandibular condyle, and mandibular retrusion. High-resolution temporal bone CT evaluates stenosis or atresia of the external auditory canal, ossicular malformations (malleus-incus fusion, incus-stapes discontinuity, etc.), reduced middle ear volume, and whether the cochlea and semicircular canals are normal. The fact that the cochlea and inner ear structures are mostly preserved as normal is the basis for using bone conduction hearing aids (BAHA). Airway evaluation signs: polysomnography (PSG) shows an increased apnea-hypopnea index (AHI). Choanal stenosis may be observed on nasal endoscopy. In some cases, evaluation of hypopharyngeal and glottic structures by flexible bronchoscopy is needed.
There is no population-wide newborn screening test for mandibulofacial dysostosis, but prenatal ultrasound and newborn hearing screening serve a practical screening function.
Prenatal ultrasound: on routine 2nd- and 3rd-trimester ultrasound, the following findings raise suspicion of mandibulofacial dysostosis. ① Small or deformed fetal auricles (microtia), ② mandibular retrusion and micrognathia (receding chin), ③ flattening of the cheeks due to zygomatic hypoplasia, ④ polyhydramnios (when swallowing difficulty is present). However, facial findings are often hard to recognize on prenatal ultrasound, so diagnostic sensitivity is low. Prenatal MRI allows more precise evaluation of fetal facial structures and is particularly useful when severe micrognathia is suspected.
Newborn hearing screening: when a 'bilateral refer' result is obtained on otoacoustic emission (OAE) or automated auditory brainstem response (AABR) testing in the universal Newborn Hearing Screening program, mandibulofacial dysostosis is differentiated together with an assessment of facial morphology. In conductive hearing loss, OAE testing is often impossible or gives poor results because of external auditory canal atresia, so AABR testing is preferred. Family history-based screening: in pregnancies with an affected parent, whether the fetus is affected is confirmed by prenatal genetic analysis (CVS or amniocentesis). Because parents with a mild phenotype may be mistaken as unaffected, clinical and genetic evaluation of all family members contributes to improved screening accuracy. Neonatal airway screening: in newborns with severe micrognathia, it is important to assess the risk of airway obstruction early. Oxygen saturation monitoring immediately after birth, observation for hypoxemia during feeding, and, if needed, early polysomnography are performed.
Diagnosis of mandibulofacial dysostosis includes confirmation of characteristic clinical findings and identification of the molecular genetic cause. The goals of diagnosis are ① to establish the clinical diagnosis of mandibulofacial dysostosis, ② to identify the causative gene variant, and ③ to quantify hearing, airway, and facial abnormalities and establish a surgical plan.
Clinical diagnostic criteria: the clinical diagnosis of mandibulofacial dysostosis is made from a combination of the following major findings. ① Downslanting palpebral fissures, ② zygomatic hypoplasia or absence, ③ lower eyelid coloboma, ④ microtia and external auditory canal atresia, ⑤ micrognathia and mandibular retrusion, ⑥ conductive hearing loss. The diagnosis is made clinically when 5 or more of these are present. However, in mild phenotypes only some findings may appear, making clinical diagnosis difficult.
Imaging: 3D-reconstructed facial CT (evaluation of the shape and defects of the zygomatic arch and mandible) and high-resolution temporal bone CT (evaluation of external auditory canal, middle ear, and ossicular abnormalities) are essential. These studies are used directly for hearing rehabilitation (determining indications for bone conduction hearing aids or cochlear implants) and planning of facial reconstruction surgery. Intracranial abnormalities are rare in mandibulofacial dysostosis, but if needed, brain MRI is used to rule out accompanying brain malformations.
Hearing tests: the type and degree of hearing loss are quantified by pure-tone audiometry (PTA), otoacoustic emissions (OAE), and auditory brainstem response (ABR). In newborns, hearing thresholds are estimated by AABR or ABR, and as age increases, behavioral audiometry (play audiometry, pure tone audiometry) is added. Middle ear function is evaluated by impedance audiometry. Molecular genetic testing: TCOF1 (whole-gene sequencing and deletion/duplication analysis) is performed first, and if negative, POLR1D (AD/AR) and POLR1C (AR) testing is added. Some institutions perform a mandibulofacial dysostosis/craniofacial malformation panel including the three genes as the first-line test. Based on the genetic test results, the recurrence risk is calculated, parental carrier status is confirmed, and prenatal diagnosis is planned. Airway evaluation: airway anatomy is evaluated by polysomnography (PSG) and, if needed, flexible laryngoscopy/bronchoscopy. Pre-anesthetic airway evaluation is also essential for surgical planning.
Treatment of mandibulofacial dysostosis requires a long-term multidisciplinary approach including securing the airway, hearing rehabilitation, staged facial reconstruction surgery, speech therapy, and psychological support. Each stage of treatment is planned according to age and developmental stage.
Neonatal airway management: when there is airway obstruction due to severe micrognathia, immediate airway securement is the top priority. Mild cases can be managed with prone positioning and a nasopharyngeal airway, but in moderate or worse cases an oropharyngeal airway, CPAP (continuous positive airway pressure), or a high-flow nasal cannula (HFNC) is used. Internal mandibular distraction osteogenesis (MDO) is a method of gradually advancing the mandible in the neonatal period to widen the airway and is effective in avoiding tracheostomy or allowing early removal of an existing tracheostomy. However, when endoscopic endotracheal intubation is extremely difficult (severe micrognathia, limited mouth opening), neonatal tracheostomy is unavoidable.
Hearing rehabilitation: when conductive hearing loss due to external auditory canal atresia and ossicular abnormalities is present, early hearing rehabilitation from the neonatal period is decisive for language development. In patients with external auditory canal atresia, a bone-anchored hearing aid (BAHA) is an effective first choice. A BAHA transmits vibration to the inner ear through an implant fixed directly to the skull; in infancy a headband-type device is used, and the implant is inserted after age 4–5, when the skull is thick enough. Ossicular reconstruction surgery (middle ear reconstruction, ossiculoplasty) is performed when cochlear function is preserved, but because its success rate is limited, the decision is made carefully. Staged facial reconstruction surgery: facial reconstruction is planned in several stages according to growth. Zygomatic and orbital reconstruction (rib and calvarial bone grafts or Medpor implants, after age 5–7) contributes to improved facial shape and orbital support. Mandibular reconstruction (mandibular distraction osteogenesis or graft reconstruction, at age 6–10 and after growth is complete) aims to correct micrognathia and improve occlusion. External ear reconstruction (autologous rib cartilage graft, age 6–10) is achieved through multistage surgery. Correction of lower eyelid coloboma is performed by ophthalmic eyelid plastic surgery for corneal protection and facial aesthetics. After growth is complete (age 18 or older), orthognathic surgery, facial prostheses, and additional facial corrective surgery correct the final facial shape. Speech therapy: early speech therapy is started at the same time as hearing rehabilitation. When cleft palate is present, cleft palate surgery (palatoplasty, at 10–12 months of age) and speech therapy are needed. Psychological support: psychological counseling and family support for psychological difficulties, peer bullying, and low self-esteem related to facial dysmorphism are important.
The prognosis of mandibulofacial dysostosis varies with the adequacy of treatment, the timing of hearing rehabilitation, the success of airway management, and surgical outcomes.
Intelligence and cognitive development: because there is no raised intracranial pressure in mandibulofacial dysostosis, intelligence is normal in most cases. If hearing loss is not adequately rehabilitated early, delayed language development, learning disabilities, and difficulty adjusting to school may occur. In contrast, when early hearing rehabilitation is achieved, language development and academic achievement are within the normal range. Some studies have reported that the average IQ of patients with mandibulofacial dysostosis is normal and that many adult patients complete higher education and achieve occupational success.
Hearing prognosis: after hearing rehabilitation with a bone-anchored hearing aid (BAHA), speech reception improves greatly, and the prognosis for language development is best when it is applied early (neonatal period to infancy). The success rate of ossicular reconstruction surgery is limited (30–50%), but when successful, hearing improvement using air conduction is possible. Airway prognosis: the airway improves after mandibular distraction or mandibular reconstruction surgery and tends to widen further with growth. In a substantial proportion of patients who underwent tracheostomy, decannulation is possible after growth. Facial appearance and psychosocial prognosis: facial appearance improves gradually with staged facial reconstruction surgery. However, facial dysmorphism is often not completely corrected, and the resulting social stigma, difficulties at school, and psychological problems are important long-term challenges. Inclusive education with peer groups, psychological support, and self-advocacy skills training are key to social adjustment. Employment rates and the level of social participation in adulthood depend greatly on the adequacy of early rehabilitation and psychological support. Because quality of life is strongly influenced by psychosocial factors in addition to physical function, social welfare support should be provided alongside the medical team.
Complete primary prevention of mandibulofacial dysostosis is currently impossible. However, genetic counseling, prenatal diagnosis, and prevention of complications through early hearing and airway rehabilitation are important preventive strategies.
Genetic counseling and prenatal diagnosis: the risk to the children of a patient with an autosomal dominant TCOF1 or POLR1D variant is 50%. With parents who are carriers of an autosomal recessive POLR1C variant, 25% of children are affected. In families with an identified genetic cause, whether the fetus is affected is confirmed by genetic analysis through prenatal CVS or amniocentesis. Preimplantation genetic testing (PGT) is also possible for both AD and AR forms. When a parent with a mild phenotype is a carrier, thorough counseling is needed that a more severe phenotype may be expressed in the child.
Prevention of airway complications (secondary prevention): in newborns with severe micrognathia, a prenatal airway plan (ex utero intrapartum treatment, EXIT procedure) is established so that immediate airway securement is possible at delivery. The neonatal airway status is closely monitored, and airway intervention is performed immediately when signs of airway obstruction appear. Prevention of delayed language development due to hearing loss: when a refer result is obtained on newborn hearing screening, the '1-3-6 principle' is followed, aiming for detailed hearing evaluation within 1 month of age, diagnosis within 3 months, and start of hearing rehabilitation within 6 months. A BAHA headband hearing aid is applied from a few months of age to maximize auditory stimulation. Early language stimulation and speech therapy are key to preventing delayed language development. Psychosocial prevention: family psychological support is started at the time of diagnosis, and training in interaction with peer groups is provided before school entry. Public education to overcome social prejudice about facial dysmorphism and connection with patient support groups are important.
Treacher Collins Syndrome Collaborative Group. Positional cloning of a gene involved in the pathogenesis of Treacher Collins syndrome. Nat Genet. 1996;12(2):130-136. DOI: 10.1038/ng0296-130. PMID: 8563749.
Trainor PA, Dixon J, Dixon MJ. Treacher Collins syndrome: etiology, pathogenesis and prevention. Eur J Hum Genet. 2009;17(3):275-283. DOI: 10.1038/ejhg.2008.221. PMID: 19081645.
Dauwerse JG, Dixon J, Seland S, et al. Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome. Nat Genet. 2011;43(1):20-22. DOI: 10.1038/ng.724. PMID: 21131976.
Dixon J, Jones NC, Sandell LL, et al. Tcof1/Treacle is required for neural crest cell formation and proliferation deficiencies that cause craniofacial abnormalities. Proc Natl Acad Sci USA. 2006;103(36):13403-13408. DOI: 10.1073/pnas.0603730103. PMID: 16938878.
Jones NC, Lynn ML, Gaudenz K, et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat Med. 2008;14(2):125-133. DOI: 10.1038/nm1725. PMID: 18246079.
Poswillo D. The pathogenesis of the Treacher Collins syndrome (mandibulofacial dysostosis). Br J Oral Surg. 1975;13(1):1-26. DOI: 10.1016/0007-117x(75)90019-8. PMID: 1056701.
Katsanis SH, Jabs EW. Treacher Collins syndrome. In: Adam MP, et al., eds. GeneReviews. NCBI Bookshelf; 2004 [updated 2023]. PMID (bookshelf): NBK1532.
Luquetti DV, Heike CL, Hing AV, Cunningham ML, Cox TC. Microtia: epidemiology and genetics. Am J Med Genet A. 2012;158A(1):124-139. DOI: 10.1002/ajmg.a.34352. PMID: 22106044.
Argenta LC, Iacobucci JJ. Treacher Collins syndrome: present concepts of the disorder and their surgical correction. World J Surg. 1989;13(4):401-409. DOI: 10.1007/BF01660755. PMID: 2672435.
Macnamara M, Albert DM, Bailey CM, Phelps PD, Bellman SC. Clicking tinnitus and bilateral sensorineural hearing loss in Treacher-Collins syndrome. J Laryngol Otol. 1994;108(3):239-241. DOI: 10.1017/s0022215100126350. PMID: 8163875.